Borealis Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Borealis Biosciences, Inc. - overview
Established
2024
Location
Vancouver, BC, Canada
Primary Industry
Biotechnology
About
Founded in 2024 by David Powell, and based in British Columbia, Canada, Borealis Biosciences, Inc. operates as a biotechnology research company that develops RNA drugs for treating kidney diseases. In December 2024, Borealis Biosciences raised USD 30 million in series A funding led by new investor Westlake Village BioPartners. Borealis Biosciences is a company focused on developing RNA medicines to address kidney diseases and potentially other conditions.
It was established based on the belief that recent scientific and translational advancements make RNA-based therapies viable for treating these diseases. The company is supported by Versant Ventures and Novartis AG, with whom it has a strategic collaboration. The company intends to use the December 2024 funding to advance its RNA-based therapeutic programs targeting kidney diseases.
Current Investors
Versant Ventures, Novartis, Westlake Village BioPartners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.borealisbio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.